Clinical trial
Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Proof-of-concept Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder
NCT04753164 is registered in ClinicalTrials.gov with Idorsia Pharmaceuticals Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Proof-of-concept Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 16, 2021
- Completion date
- March 25, 2022
- Enrollment
- 136 (actual)
- Sites
- 30
Conditions
As the registry lists them; a condition with its own page is linked.